In a landmark moment for African science and global drug research, Professor Ene Ikpong Ette was recently announced as the 2025 recipient of the Sheiner-Beal Pharmacometrics Award. The honour, which is the highest accolade in the field of pharmacometrics, was conferred by the American Society for Clinical Pharmacology and Therapeutics (ASCPT) at its annual meeting in May. With that recognition, Ette became the first Black scientist to receive the “Nobel Prize” of pharmacometrics.
To understand the context of this award and its significance, it is important to know that pharmacometrics is one of the hidden engines behind modern precision medicine, and Prof. Ette’s work laid much of the groundwork for its prominence. The discipline is the science of interpreting and describing pharmacology in a quantitative way. Simply put, it uses mathematical models, statistics, and simulations to understand pharmacokinetics and pharmacodynamics. It provides a scientific framework to predict drug responses, optimise dosing, reduce trial-and-error in drug development, and improve patient outcomes.
Essentially, instead of testing endlessly on large populations, pharmacometricians build predictive models that integrate data from preclinical studies, clinical trials, and patient outcomes. This helps regulators, clinicians, and drug developers make informed decisions about safety, efficacy, and dosage. It is especially vital when developing medicines for children, the elderly, or populations where traditional trials are difficult or risky.
Trailblazing accomplishments
Ette was among the first to advocate for integrating pharmacometrics into every stage of drug development. “Pharmacometrics wasn’t a popular or easy path when I chose it,” he recalls. “It required advanced mathematics, statistics, programming, and pharmacology. But the Lord encouraged me to persevere and gave me the wisdom to succeed.”
This model-based approach that Ette helped pioneer allows companies and regulators to make smarter, data-driven decisions, saving time and cost in bringing drugs to market. He has published extensively and created scholarly platforms where pharmacometricians worldwide can share ideas and refine methods. He has also trained and mentored countless young scientists, especially from underrepresented backgrounds, equipping them with the skills to apply pharmacometric methods globally.
The ASCPT particularly recognised Ette for helping to draft the landmark 1999 FDA Guidance for Industry: Population Pharmacokinetics, a document that transformed the global landscape of drug development, ushering in a model-informed, data-driven approach that laid the foundation for present-day precision medicine. His research and advocacy helped shape how the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) now incorporate pharmacometric evaluations into drug approval processes. Today, regulators routinely expect pharmacometric analyses in new drug applications, a development that Ette helped popularise.
Ette is also acclaimed as an inventor and co-inventor, with several patents- including the first ever reduction in hepatitis C treatment duration from 48 to 24 weeks with telaprevir. He equally helped to establish the first US certificate programme in pharmacometrics (at the University of North Texas Health Science Centre), expanding the pipeline for the next generation of experts.
Triumph of diligence and persistence
Not only was the ASCPT award a deeply personal moment for Ette, it was also a victory for a discipline he has spent decades championing. According to him: “This award is not just recognition of my individual contributions to pharmacometrics; it’s a validation of the collective power of innovation, collaboration, and a commitment to advancing healthcare. It is a reminder of the importance of perseverance and of aligning one’s purpose with action.”
Ette has over 30 years of broad experience in academia, drug evaluation and regulation, and the pharmaceutical industry, where he has held several senior positions. He is currently the President and CEO of Anoixis Corporation, a clinical pharmacology, pharmacometrics, and statistical consulting company that he co-founded. He has consistently led his team of experts to support several pharmaceutical and biopharmaceutical companies in the development of compounds from preclinical to registration in oncology, bio-oncology, gastroenterology, immunology, microbiology, virology, epilepsy, and pain, to name a few therapeutic areas.
“He is also an Honorary Professor of Clinical Pharmacology/Pharmacometrics, Faculty of Medicine, University of Namibia, as well as being the senior editor of the classic reference text Pharmacometrics: The Science of Quantitative Pharmacology.
Erudite foundations
Prof Ette was born and raised in Nwaniba, 9 miles from Uyo in present-day Akwa Ibom State. Between the 1950s and the 1960s. He attended Lutheran High School, Obot Idim, and found himself drawn to the precision and logic of science and mathematics – subjects that would ultimately define his career path.
He studied Pharmacology at the University of Ibadan (1974–1977), then earned a master’s degree, also in Pharmacology, from the University of Ife (now Obafemi Awolowo University) in 1980. Later, he crossed the Atlantic to earn a second degree in Pharmacy from Northeastern University in the United States (1983), a PhD in Clinical Pharmacology (with specialisation in Pharmacometrics) from the University of Glasgow (1992), and an MBA in Entrepreneurship from the University of North Alabama (2005).
It was an unusual combination of disciplines, but in hindsight it foreshadowed the way he would blend technical science with strategic thinking. In his words: “You can have the science, but if you don’t know how to connect it to strategy, policy, and people, its impact will be limited.”
Countdown to greatness
Working directly on reviewing new drug applications and conducting research on the design and analysis of population pharmacokinetic studies, he witnessed firsthand the limitations of traditional analyses of these studies and strongly advocated an informative model-based pharmacometrics approach.
It was within this time that much of the conceptual framework for the groundbreaking Population PK Guidance, published in 1999, was developed. Two decades on, that guidance is still used around the world and remains a cornerstone of precision medicine.
When Ette moved to Vertex Pharmaceuticals in 1997, as Senior Director and Global Head of the Department of Clinical Pharmacology, his innovative spirit was immediately apparent. Among his litany of accomplishments, he helped develop a regimen for hepatitis C that reduced treatment duration from 48 weeks to 24. It was a breakthrough that eased the burden for thousands of patients.
“Ene’s innovative ideas brought truly breakthrough drug development,” recalls a former colleague, Dr Alaa Ahmad. “His leadership gave the quantitative proof we needed to halve treatment time without compromising outcomes.”
Honours and recognitions
He is a Fellow of the African Academy of Sciences, a Fellow of the American Colleges of Clinical Pharmacology and Clinical Pharmacy, a Fellow of the American Association of Pharmaceutical Sciences, and a senior Fulbright Specialist Fellow.
He is the first black/African recipient of the Russell Miller Award for outstanding contributions to the clinical pharmacy literature, the first black/African recipient of the Therapeutic Frontier Lecture Award for distinguished scientific achievement. The Award, which is the highest award of the American College of Clinical Pharmacy (ACCP), is presented by the ACCP to an internationally recognized scientist for his/her outstanding contributions to pharmacotherapeutics. The awardee is at the forefront of pharmacotherapeutic research. He is also the 1996 FDA Excellence in Review Science Awardee. His peers see him as not only a pioneer in pharmacometrics but also as someone who has advanced the profession’s credibility at the highest levels of science and policy.
